

Title (en)
USE OF A COMPLEMENT ACTIVATION INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING SIDE EFFECTS OF PHARMACEUTICAL COMPOSITIONS CONTAINING AMPHIPHILIC VEHICLES OR DRUG CARRIER MOLECULES

Title (de)
VERWENDUNG VON INHIBITOREN DER KOMPLEMENTAKTIVIERUNG ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR INHIBIERUNG VON NEBENWIRKUNGEN VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN, DIE AMPHIPHILE TRÄGER ODER WIRKSTOFFTRÄGER MOLEKÜLE ENTHALTEN

Title (fr)
UTILISATION D'UN INHIBITEUR D'ACTIVATION DE COMPLEMENT POUR PREPARER UN MEDICAMENT POUR INHIBER LES EFFETS SECONDAIRES DE COMPOSITIONS PHARMACEUTIQUES CONTENANT DES EXCIPIENTS AMPHIPHILES OU DES MOLECULES VECTEURS DE MEDICAMENTS

Publication
EP 0996461 B1 20050112 (EN)

Application
EP 98956455 A 19981030

Priority
• US 9823280 W 19981030
• US 6387697 P 19971031

Abstract (en)
[origin: WO9922759A1] A method is provided for inhibiting or preventing toxicity and other unwanted effects (a) caused by solvents for pharmaceuticals which solvents or emulsifier which contain amphiphilic molecules such as polyethoxylated oils or a derivative thereof, or (b) caused by a drug in a vehicle containing amphiphilic molecules such as phospholipids or derivative thereof, employing a complement inhibitor. Drug compositions containing amphiphilic molecules, or derivatives thereof and a complement inhibitor, and pharmaceutical compositions including a drug, solvent or carrier containing amphiphilic molecules or derivatives thereof, and a complement inhibitor are also provided.

IPC 1-7
A61K 38/17; **A61K 38/48**; **A61K 38/55**; **A61P 37/00**

IPC 8 full level
A61K 38/17 (2006.01); **A61K 38/48** (2006.01); **A61K 38/55** (2006.01)

CPC (source: EP US)
A61K 9/127 (2013.01 - EP US); **A61K 31/337** (2013.01 - EP US); **A61K 31/498** (2013.01 - EP US); **A61K 31/5513** (2013.01 - EP US); **A61K 31/57** (2013.01 - EP US); **A61K 31/704** (2013.01 - EP US); **A61K 31/7048** (2013.01 - EP US); **A61K 38/177** (2013.01 - EP US); **A61K 38/42** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 37/00** (2017.12 - EP); **A61P 39/00** (2017.12 - EP)

C-Set (source: EP US)
1. **A61K 31/337** + **A61K 2300/00**
2. **A61K 31/498** + **A61K 2300/00**
3. **A61K 31/5513** + **A61K 2300/00**
4. **A61K 31/57** + **A61K 2300/00**
5. **A61K 31/704** + **A61K 2300/00**
6. **A61K 31/7048** + **A61K 2300/00**
7. **A61K 38/177** + **A61K 2300/00**
8. **A61K 38/42** + **A61K 2300/00**

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9922759 A1 19990514; **WO 9922759 A9 19990812**; AT E286743 T1 20050115; AU 1297899 A 19990524; CA 2298475 A1 19990514; DE 69828615 D1 20050217; DE 69828615 T2 20051201; EP 0996461 A1 20000503; EP 0996461 B1 20050112; US 2002136759 A1 20020926; US 2008107724 A1 20080508; US 7419683 B2 20080902

DOCDB simple family (application)
US 9823280 W 19981030; AT 98956455 T 19981030; AU 1297899 A 19981030; CA 2298475 A 19981030; DE 69828615 T 19981030; EP 98956455 A 19981030; US 18337598 A 19981030; US 98062007 A 20071031